Category: finance stock

FDA approves Gilead’s Remdesivir as Covid-19 treatment

FDA approves Gilead’s Remdesivir as Covid-19 treatment

The FDA has approved Gilead’s Remdesivir as a Covid-19 treatment. Previously, the drug was approved only for emergency authorization. Gilead stock was up 4 percent after the news. Meg Tirrell joins ‘Closing Bell’ to discuss. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision […]

White House advisor Larry Kudlow: It’s an ‘optimistic morning’ for coronavirus stimulus talks

White House advisor Larry Kudlow: It’s an ‘optimistic morning’ for coronavirus stimulus talks

White House economic advisor Larry Kudlow joins “Squawk on the Street” to discuss the push for new stimulus as Congress and the White House remain at odds. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to […]

White House, Congress remain locked in negotiations on coronavirus stimulus — Here’s the latest

White House, Congress remain locked in negotiations on coronavirus stimulus — Here’s the latest

The White House, House Democrats and Senate Republicans are still working on a stimulus deal. The sides have come closer to finding common ground on Covid-19 testing, but remain divided on state and local government relief and liability protections for businesses. House speaker Nancy. Pelosi downplayed the importance of an end-of-Tuesday deadline she had set.

Fmr. FDA chief: ‘Hardest part’ of coronavirus pandemic lies ahead for U.S.

Fmr. FDA chief: ‘Hardest part’ of coronavirus pandemic lies ahead for U.S.

Former FDA commissioner Scott Gottlieb joins CNBC’s “Squawk Box” to discuss the state of the vaccine race and the eventual winner’s distribution scenarios. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn […]

Bill Gates criticizes U.S. Covid-19 response: Most governments listen to their scientists

Bill Gates criticizes U.S. Covid-19 response: Most governments listen to their scientists

Billionaire philanthropist Bill Gates, co-founder of Microsoft, criticized the U.S. response to the coronavirus, telling CNBC the nation ranks “quite low compared to other countries” in executing testing and delivering a clear message on safe social practices such as wearing masks. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi […]

Pfizer board member Dr. Scott Gottlieb details likelihood of coronavirus vaccine in late November

Pfizer board member Dr. Scott Gottlieb details likelihood of coronavirus vaccine in late November

Dr. Scott Gottlieb, former FDA commissioner and Pfizer board member, joins “Closing Bell” to discuss comments from Pfizer that a vaccine is likely by the end of November. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi Pfizer said on Friday it may file for authorization of the Covid-19 vaccine […]

Jim Cramer: Investors will regret selling U.S. stocks on Europe Covid-19 spikes

Jim Cramer: Investors will regret selling U.S. stocks on Europe Covid-19 spikes

CNBC’s Jim Cramer on Thursday advised investors against selling U.S. equities in response to spiking coronavirus cases across European nations. Subscribe to CNBC PRO for access to investor and analyst insights: https://cnb.cx/2Vtntx6 CNBC’s Jim Cramer on Thursday advised investors against selling U.S. equities in response to spiking coronavirus cases across European nations. “If you follow […]

Jim Cramer on Johnson & Johnson pausing its coronavirus vaccine trial after ‘adverse event’

Jim Cramer on Johnson & Johnson pausing its coronavirus vaccine trial after ‘adverse event’

The study of Johnson & Johnson’s Covid-19 vaccine has been paused due to an unexplained illness in a study participant. CNBC’s Jim Cramer and David Faber discuss the development and whether it affects Johnson & Johnson’s stocks. Subscribe to CNBC PRO for access to investor and analyst insights: https://cnb.cx/2Vtntx6 » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision […]

Next Page »